Abstract 517P
Background
The prognostic predictive value of breast cancer susceptibility gene 1 (BRCA1) for non-small-cell lung cancer (NSCLC) remains controversial. This study aimed to determine the prognostic effect of BRCA1 on NSCLC survival using meta-bioinformatic analysis.
Methods
Candidate articles were identified from PubMed, Embase, Cochrane Library, and Web of Science databases. Effect measures generated were the pooled hazard ratio (HR) and 95% confidence interval (CI). Cox regression model was performed in an independent dataset from TCGA to validate the accuracy of our meta-analysis.
Results
A total of 2462 patients from 15 studies of acceptable quality were included. No significant differences in overall survival (OS)/cancer-specific survival (CSS) (HR = 1.38, 95% CI: 0.95-2.00, P = 0.094) or progression-free survival (PFS)/disease-free survival (DFS)/relapse-free survival (RFS) (HR = 1.28, 95% CI: 0.82-2.00, P = 0.284) were observed between patients with high- and low-expression of BRCA1. However, patients with lung adenocarcinoma (LUAD) and increased BRCA1 expression had markedly poorer OS/CSS (HR = 1.78, 95% CI: 1.05-3.03, P = 0.032) than those with reduced BRCA1. Bioinformatics analysis also indicated that BRCA1 overexpression was independently correlated with decreased OS in LUAD. Moreover, patients with high BRCA1 were more likely to suffer from lymph node metastasis than those with low BRCA1.
Conclusions
Elevated BRCA1 expression may be a novel biomarker of poor OS for patients with LUAD.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract